Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0K6MW
|
|||
Former ID |
DNAP001497
|
|||
Drug Name |
Teicoplanin
|
|||
Synonyms |
Targocid (TN)
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1], [2] | |
Company |
Sanofi-Aventis
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C88H97Cl2N9O33
|
|||
Canonical SMILES |
CCCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)O
|
|||
InChI |
1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88?/m1/s1
|
|||
InChIKey |
BJNLLBUOHPVGFT-CAYRISATSA-N
|
|||
CAS Number |
CAS 61036-62-2
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ADReCS Drug ID | BADD_D02141 | |||
SuperDrug ATC ID |
J01XA02
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
Studied Microbe: Staphylococcus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Staphylococcus was decreased by Teicoplanin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterococcus was increased by Teicoplanin. | |||
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Lactobacillus was increased by Teicoplanin. | |||
Studied Microbe: Pediococcus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Pediococcus was increased by Teicoplanin. |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bacterial Cell membrane (Bact CM) | Target Info | Inhibitor | [1], [4] |
References | Top | |||
---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 2 | ClinicalTrials.gov (NCT00719056) Teicoplanin Prophylaxis for Total Hip or Knee Arthroplasty. U.S. National Institutes of Health. | |||
REF 3 | Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis. 1996 May;173(5):1129-36. | |||
REF 4 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.